Mechanisms of impaired bone strength in type 1 and 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 9, 2010, Pages 683-690

  Merlotti, D ^a   Gennari, L ^a   Dotta, F ^a   Lauro, D ^b   Nuti, R ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bone strength; Diabetes; Fracture; Glucose toxicity; Osteoporosis

Indexed keywords

ANTIDIABETIC AGENT;

AGED; BONE; BONE DENSITY; BONE REMODELING; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TENSILE STRENGTH;

AGED; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; TENSILE STRENGTH;

EID: 78049407620     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.07.008     Document Type: Review

References (70)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007, 18:427-444. 10.1007/s00198-006-0253-4.
2. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis 2009 Jun, 19(5):365-377. 10.1016/j.numecd.2009.03.018.
3. Maurer M.S., Burcham J., Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005, 60:1157-1162.
4. Inaba M., Okuno S., Kumeda Y., Yamakawa T., Ishimura E., Nishizawa Y. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005, 76:256-260. 10.1007/s00223-004-0094-0.
5. Rix M., Andreassen H., Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999, 22:827-831. 10.2337/diacare.22.5.827.
6. Vogt M.T., Cauley J.A., Kuller L.H., Nevitt M.C. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997, 12:283-289. 10.1359/jbmr.1997.12.2.283.
7. Hofbauer L.C., Brueck C.C., Singh S.K., Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007, 22:1317-1328. 10.1359/jbmr.070510.
8. McCabe L.R. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007, 102:1343-1357. 10.1002/jcb.21573.
9. Gunczler P., Lanes R., Paz-Martinez V., Martins R., Esaa S., Colmenares V., et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 1998, 11:413-419.
10. Pascual J., Argente J., Lopez M.B., Munoz M., Martinez G., Vazquez M.A., et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 1998, 62:31-35. 10.1007/s002239900390.
11. Valerio G., del Puente A., Esposito-del Puente A., Buono P., Mozzillo E., Francese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 2002, 58:266-272. 10.1159/000066441.
12. Moyer-Mileur L.J., Slater H., Jordan K.C., Murray M.A. IGF-1 and IGF-binding proteins and bone mass, geometry and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 2008, 23:1884-1891.
13. Liu E.Y., Wactawski-Wende J., Donahue R.P., Dmochowski J., Hovey K.M., Quattrin T. Does low bone mineral density start in post-teenage years in women with type 1 diabetes?. Diabetes Care 2003, 26:2365-2369.
14. Strotmeyer E.S., Cauley J.A., Orchard T.J., Steenkiste A.R., Dorman J.S. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 2006, 29:306-311.
15. Clausen P., Feldt-Rasmussen B., Jacobsen P., Rossing K., Parving H.H., Nielsen P.K., et al. Microalbuminuria as an early indicator of osteopenia in male insulin dependent diabetic patients. Diabet Med 1997, 14:1038-1043.
16. Miao J., Brismar K., Nyren O., Ugarph-Morawski A., Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in sweden. Diabetes Care 2005, 28:2850-2855.
17. Schwartz A.V. Impact of diabetes and its treatment on bone. Clin Rev Bone Miner Metab 2009, 7:249-260.
18. Strotmeyer E.S., Cauley J.A., Schwartz A.V., Nevitt M.C., Resnick H.E., Zmuda J.M., et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the health, aging, and body composition study. J Bone Miner Res 2004, 19:1084-1091.
19. de Liefde I., van der Klift M., de Laet C.E., van Daele P.L., Hofman A., Pols H.A. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam study. Osteoporos Int 2005, 16:1713-1720.
20. Leslie W.D., Lix L.M., Prior H.J., Derksen S., Metge C., O'Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone 2007, 40:1595-1601. 10.1016/j.bone.2007.02.021.
21. Schwartz A.V., Sellmeyer D.E., Strotmeyer E.S., Tylavsky F.A., Feingold K.R., Resnick H.E., et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005, 20:596-603.
22. Melton L.J., Riggs B.L., Leibson C.L., Achenbach S.J., Camp J.J., Bouxsein M.L., et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008, 93:4804-4809.
23. Petit M., Paudel M.L., Taylor B., Hughes J., Strotmeyer E.S., Schwartz A.V., et al. Bone mass and strength in older men with type II diabetes: the osteoporotic fractures in men study. J Bone Miner Res 2010, 25:285-291.
24. Burghardt A.J., Kazakia G.J., Ramachandran S., Link T.M., Majumdar S. Age and gender related differences in the geometric properties and biomechanical significance of intra-cortical porosity in the distal radius and tibia. J Bone Miner Res 2010, 25:983-993.
25. Williams J.P., Blair H.C., McDonald J.M., McKenna M.A., Jordan S.E., Williford J., et al. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun 1997, 235:646-651. 10.1006/bbrc.1997.6795.
26. Saito M., Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010, 21:195-214.
27. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
28. Viguet-Carrin S., Gineyts E., Bertholon C. Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single column high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1-7. 10.1016/j.jchromb.2008.10.043.
29. Viguet-Carrin S., Roux J.P., Arlot M.E., Merabet Z., Leeming D.J., Byrjalsen I., et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006, 39:1073-1079. 10.1016/j.bone.2006.05.013.
30. Vashishth D., Gibson G.J., Khoury J.I., Schaffler M.B., Kimura J., Fyhrie D.P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:195-201. 10.1016/S8756-3282(00)00434-8.
31. Odetti P., Rossi S., Monacelli F., Poggi A., Cirnigliaro M., Federici M., et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005, 1043:710-717.
32. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013-1019.
33. Schwartz A.V., Garnero P., Hillier T.A., Sellmeyer D.E., Strotmeyer E.S., Feingold K.R., et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:2380-2386.
34. Yamamoto M., Yamaguchi T., Yamauchi M., Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 2009, 32:2263-2268.
35. McCarthy A.D., Etcheverry S.B., Bruzzone L., Cortizo A.M. Effects of advanced glycation endproducts on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem 1997, 170:43-51.
36. Campos Pastor M.M., López-Ibarra P.J., Escobar-Jiménez F., Serrano Pardo M.D., García-Cervigón A.G. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000, 11:455-459.
37. Krakauer J.C., McKenna M.J., Buderer N.F., Rao D.S., Whitehouse F.W., Parfitt A.M. Bone loss and bone turnover in diabetes. Diabetes 1995, 44:775-782.
38. Conover C.A., Lee P.D., Riggs B.L., Powell D.R. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology 1996, 137:3295-3301.
39. Ogata N., Chikazu D., Kubota N., Terauchi Y., Tobe K., Azuma Y., et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000, 105:935-943.
40. Irwin R., Lin H.V., Motyl K.J., McCabe L.R. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology 2006, 147:5760-5767.
41. Maor G., Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology 1999, 140:1841-1851.
42. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008, 29:535-559.
43. Bereket A., Lang C.H., Wilson T.A. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 1999, 31:172-181.
44. Crowne E.C., Samra J.S., Cheetham T., Acerini C.L., Watts A., Holly J.M., et al. The role of IGFbinding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus. J Clin Endocrinol Metab 2001, 86:3686-3691.
45. Reid I.R. Relationships between fat and bone. Osteoporos Int 2008, 19:595-606.
46. Baynes K.C., Boucher B.J., Feskens E.J., Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997, 40:344-347.
47. Gysemans C., Van Etten E., Overbergh L., Verstuyf A., Waer M., Bouillon R., et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin- D3. Clin Exp Immunol 2002, 128:213-220.
48. Schäffler A., Müller-Ladner U., Schölmerich J., Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006, 27:449-467.
49. Hamrick M.W., Ferrari S.L. Leptin and the sympathetic connection of fat to bone. Osteoporos Int 2008, 19:905-912.
50. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009, 160:265-273.
51. Okazaki R., Totsuka Y., Hamano K., Ajima M., Miura M., Hirota Y., et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997, 82:2915-2920.
52. Manolagas S.C., Almeida M. Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007, 21:2605-2614.
53. Lipscombe L.L., Jamal S.A., Booth G.L., Hawker G.A. The risk of hip fractures in older individuals with diabetes: a population based study. Diabetes Care 2007, 30:835-841.
54. Melton L.J., Leibson C.L., Achenbach S.J., Therneau T.M., Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334-1342.
55. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
56. Schwartz A.V. TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008, 2008:297893.
57. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can Med Assoc J 2009, 180:32-39.
58. Kahn S.E., Zinman B., Lachin J.M., Haffner S.M., Herman W.H., Holman R.R., et al. Rosiglitazone associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
59. Habib Z.A., Havstad S.L., Wells K., Divine G., Pladevall M., Williams L.K. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592-600. [published ahead of print]. 10.1210/jc.2009-1385.
60. Vestergaard P., Rejnmark L., Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005, 48:1292-1299.
61. Zinman B., Haffner S.M., Herman W.H., Holman R.R., Lachin J.M., Kravitz B.G., et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:134-142. ADOPT Study Group.
62. Cortizo A.M., Sedlinsky C., McCarthy A.D., Blanco A., Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Phamacol 2006, 536:38-46. 10.1016/j.ejphar.2006.02.030.
63. Ma P., Gu B., Ma J., E L., Wu X., Cao J., et al. Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism 2010 Mar, 59(3):359-366. 10.1016/j.metabol.2009.08.003.
64. White J. Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2009, 49:S30-S40.
65. Monami M., Iacomelli I., Marchionni N., Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010, 20:224-235. 10.1016/j.numecd.2009.03.015.
66. Clowes J.A., Khosla S., Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005, 20:1497-1506.
67. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Udagawa N., Takahashi N., et al. The murine glucagon like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008, 149:574-579.
68. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
69. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008, 105:5266-5270.
70. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.